2024-516141-39-00RecruitingPhase 4
EFFECT OF ONCE VS TWICE DAILY ADMINISTRATION OF CORTICOSTEROIDS ON BLOOD GLUCOSE IN PATIENTS WITH ANCA-VASCULITIS MEASURED BY CONTINUOUS BLOOD GLUCOSE MONITORING - A PILOT STUDY
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Evaluation of whether splitting the cortisone dose to a twice daily dose leads to increased time in the glucose target range.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 19 Sept 2024
- Start date
- 25 Sept 2020
- Lead sponsor
- Medical University Of Graz
- Diseases
- ANCA-associated vasculitis
- EU CT number
- 2024-516141-39-00
- EudraCT number
- 2019-002068-29
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 10
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known diabetes mellitus
- Relevant acute or chronic disease that, in the investigator's estimation, could affect the patient's safety or affect the study results.
Lab values
- Skin changes or concomitant circumstances that prevent the placement of a glucose sensor in the examiner's assessment (e.g. scar tissue)
Other
- Women capable of giving birth who are pregnant, breastfeeding, wish to become pregnant or do not use adequate contraception.
- Current participation in another clinical trial that would affect study results
- Patient's inability to follow study procedures as required
- Inability of the patient to understand the consent form
Who the study is looking for
- Written agreement to participate in the study after detailed explanation of the study
- Male or female patients
- New diagnosis of ANCA-associated vasculitis or a relapse of a known ANCA vasculitis
- Age: ≥18-80 years at the time of biopsy
- Aprednislon dose of 1mg/kg body weight at the time of inclusion
- Wants to wear a CGM system for the duration of the study and to receive insulin therapy as needed
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Graz | Graz | Austria | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.